Cargando…

Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study

Treatment options for autosomal dominant polycystic kidney disease (ADPKD) will likely become available in the near future, hence reliable diagnostic and prognostic biomarkers for the disease are strongly needed. Here, we aimed to define urinary proteomic patterns in ADPKD patients, which aid diagno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kistler, Andreas D., Serra, Andreas L., Siwy, Justyna, Poster, Diane, Krauer, Fabienne, Torres, Vicente E., Mrug, Michal, Grantham, Jared J., Bae, Kyongtae T., Bost, James E., Mullen, William, Wüthrich, Rudolf P., Mischak, Harald, Chapman, Arlene B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542378/ https://www.ncbi.nlm.nih.gov/pubmed/23326375 http://dx.doi.org/10.1371/journal.pone.0053016

Ejemplares similares

Correction: Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study
por: Kistler, Andreas D., et al.
Publicado: (2013)

Growth of arachnoid cysts in patients with autosomal dominant polycystic kidney disease: serial imaging and clinical relevance
por: Krauer, Fabienne, et al.
Publicado: (2012)

Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study
por: Serra, Andreas L, et al.
Publicado: (2007)

A comparison of ultrasound and magnetic resonance imaging shows kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease
por: Bhutani, Harpreet, et al.
Publicado: (2015)

Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease
por: El Ters, Mireille, et al.
Publicado: (2021)

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
por: Liu, Yang, et al.
Publicado: (2018)

Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort
por: McKenzie, Katelyn A., et al.
Publicado: (2018)

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
por: Grantham, Jared J., et al.
Publicado: (2017)

A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy
por: Kistler, Andreas D., et al.
Publicado: (2011)

Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients
por: Hanudel, Mark R., et al.
Publicado: (2019)

Low-Dose Oral Sirolimus and the Risk of Menstrual-Cycle Disturbances and Ovarian Cysts: Analysis of the Randomized Controlled SUISSE ADPKD Trial
por: Braun, Matthias, et al.
Publicado: (2012)

Autosomal Dominant Polycystic Kidney Disease does not significantly alter major COVID-19 outcomes among veterans
por: Cui, Xiangqin, et al.
Publicado: (2020)

Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
por: Brosnahan, Godela M., et al.
Publicado: (2018)

Urinary T cells correlate with rate of renal function loss in autosomal dominant polycystic kidney disease
por: Zimmerman, Kurt A., et al.
Publicado: (2019)

Evaluation of urine biomarkers of kidney injury in Polycystic Kidney Disease
por: Parikh, Chirag R., et al.
Publicado: (2012)

Autosomal dominant polycystic kidney
por: Gudadhe, Rugaved Raghavendra, et al.
Publicado: (2022)

Clinical Characteristics and Disease Predictors of a Large Chinese Cohort of Patients with Autosomal Dominant Polycystic Kidney Disease
por: Chen, Dongping, et al.
Publicado: (2014)

Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease
por: Sharma, Kanishka, et al.
Publicado: (2017)

A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease
por: Perrone, Ronald D., et al.
Publicado: (2017)

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
por: Devuyst, Olivier, et al.
Publicado: (2017)

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease
por: Dad, Taimur, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial
por: Shoaf, Susan E., et al.
Publicado: (2017)

Autosomal dominant polycystic kidney disease in Colombia
por: Camargo, Jessica T., et al.
Publicado: (2023)

Proteomic Candidate Biomarkers of Drug-Induced Nephrotoxicity in the Rat
por: Rouse, Rodney, et al.
Publicado: (2012)

Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data
por: Knight, Tyler, et al.
Publicado: (2015)

Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies
por: Nowak, Kristen L., et al.
Publicado: (2021)

Developments in the management of autosomal dominant polycystic kidney disease
por: Masoumi, Amirali, et al.
Publicado: (2008)

Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)
por: Sans-Atxer, Laia, et al.
Publicado: (2013)

Nephrotic syndrome and autosomal dominant polycystic kidney disease
por: Visciano, Bianca, et al.
Publicado: (2012)

Umbilical hernia in autosomal dominant polycystic kidney disease
por: Hattori, Yoshinari, et al.
Publicado: (2014)

Diagnostic Imaging of Autosomal Dominant Polycystic Kidney Disease
por: Gradzik, Monika, et al.
Publicado: (2016)

Obturator hernia in autosomal dominant polycystic kidney disease
por: Jung, Jong Hwan, et al.
Publicado: (2018)

Autosomal dominant polycystic kidney disease: updated perspectives
por: Rastogi, Anjay, et al.
Publicado: (2019)

Educational Case: Autosomal Dominant Polycystic Kidney Disease
por: Frazier, Ryan L., et al.
Publicado: (2020)

Cerebral Microbleeds in Autosomal Dominant Polycystic Kidney Disease
por: Tsai, Li-Kai, et al.
Publicado: (2020)

Clinical burden of autosomal dominant polycystic kidney disease
por: Hung, Peir-Haur, et al.
Publicado: (2020)

Drug management of autosomal dominant polycystic kidney disease
por: Theivendran, Thiveya, et al.
Publicado: (2022)

Autosomal dominant polycystic kidney disease in young adults
por: Martínez, Víctor, et al.
Publicado: (2022)

Multidisciplinary management of chronic refractory pain in autosomal dominant polycystic kidney disease
por: van Luijk, Franka, et al.
Publicado: (2022)

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial
por: Irazabal, Maria V., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tnd3h6g0nj0p75fjjqr3bkpgai